Pelletier, G., Roulot, D., Davion, T., Masliah, C., Causse, X., Oberti, F., Raabe, J.-J., Van Lemmens, C., Labadie, H., Serfaty, L., & URSOMAF Group
While the nephroprotective effects of SGLT2i were initially derived from secondary endpoints of CV outcome trials (CVOTs), direct confirmation came from dedicated kidney focused trials: CREDENCE (Perkovic et al NEJM 2019| NephJC Summary), DAPA-CKD (Heerspink et al NEJM 2020| NephJC Summary) and finally EMPAKIDNEY (Herrington et al NEJM 2023| NephJC Summary)
R., Nathan, S
Neurotrophic growth factors and their associated signaling pathways are primary contributors to brain plasticity, and dysfunction in these pathways is often correlated with depressive symptoms (Pittenger and Duman, 2008)